SNDL

SNDLA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$1.75

+36.7% vs current

Most likely

Base case

55%

Probability

Target price

$1.40

+9.4% vs current

B-

Bear case

25%

Probability

Target price

$0.95

-25.8% vs current

AI sentiment snapshot

Latest data as of 2026-07-19

AI commentary

News flow is thin and mixed. SNDL’s Q1 release reported revenue down 4.4%, gross profit down 6.8%, and negative free cash flow, while citing cost and commercial initiatives [#PR-2026-04-29]. The 1CM update removed a near-term store-growth path but highlighted planned buybacks [#PR-2026-05-27]. A July 28 earnings date is confirmed [#PR-EARNINGS-2026-07-15], but consensus, analyst reaction, social coverage, options data, and insider activity are unavailable. With evidence quality of 0.08 and uncertainty of 0.906, this remains a low-conviction monitoring view.

RankAlpha Sentiment Codex - 2026-07-19

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-07-28eventQ2 2026 results are scheduled for July 28High impact

SNDL announced it will report second-quarter 2026 results before market open on July 28 and host a conference call afterward [#PR-EARNINGS-2026-07-15]. The packet contains no consensus, guidance, or analyst-revision data, so this is a monitoring event rather than a confirmed positive catalyst.

2026-08-31eventBuyback and capital redeployment after the 1CM setbackMedium impact

The Ontario portion of the 1CM transaction was not expected to proceed because required approvals were unlikely before the outside date; SNDL said reserved capital would be redirected toward repurchases [#PR-2026-05-27].

2026-08-31catalystH2 profit-enhancement execution is the key operating checkHigh impact

SNDL described Q1 2026 as particularly challenging, with revenue and gross profit down year over year and free cash flow negative, while advancing commercial and cost initiatives intended to improve results in the remainder of 2026 [#PR-2026-04-29].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-19 • Updated nightlySource: Internal modelMethodology